Fritextsökning
Artiklar per år
Innehållstyper
-
Teams up with leading dermatologist
Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.
-
New study of toxins and heart disease
Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study will try to evaluate this, and one thousand people are to be included.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
-
A smart company takes care of its best
Lundbeck didn't have to look far to find it's new international Director of Marketing. The talent was already in the house.
-
Vitamin D is mental health aid
Vitamin D can help stave off the mental decline that can affect people in old age, a study suggests.
-
Researchers goes to the bottom of the brain
Swedish researchers have recently got new and deeper knowledge about the smallest part of the brain, the granule cells.
-
Biotage is regrouping
The Swedish company Biotage takes yet another step in streamlining efforts, by outsourcing all instrument production to contract manufacturers.
-
EUR 2 million for peanut allergies
ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.
-
Hormones make children fat
A new Danish million project will define the connection between hormons and obesity amongst children.
-
Oasmia gets a confirmation
FDA has granted Oasmia an expedited review status for Paclical Vet.
-
Finnish-Dutch engineering cooperation continues
The University of Helsinki and ASM International renew a fice year research agreement on Atomic Layer Deposition.
-
Future drugs from Amaryllis
A Danish research team has discovered possibolities to extract drugs fro Amaryllis.
-
Metabolic pro heads prefect post
The dean of the Department of Biomedicine at the Sahlgrenska Academy has appointed a new assistant prefect.
-
Biotech goes white and bright
White biotech could become Denmark's next blossoming business area.
-
Positive combined cancer therapy
Topotarget announces positive data with new treatment against colorectal cancer.
-
Medtech companies find new beam technique
The medtech companies Raysearch and Nucletron expand collaboration with two new solutions for radiation treatment planning.
-
Harmony prevents dementia
People who are active, outgoing and relaxed may be less likely to develop dementia, according to a new study from Karolinska Institutet.
-
Eli Lilly writes biotech fine history
The American biotech company Eli Lilly will pay US 1.415 billion to resolve allegations of off-label promotion of a dementia drug.
-
New nanotech professor to DTU
The Danish University of Technology, DTU, has appointed Kristoffer Almdal as professor to DTU Nanotech.
-
Swedish multi competent machine soon launched
The Swedish company Biosensor will launch new equipment able to detect twelve different narcotics and explosives simultaneously.
-
Abbott expands by acquisition
An acquisition gives Abbott a leadership position in another large and growing medical device segment.
BREAKING